Galmed Pharmaceuticals

Update in progress

GLMD (NasdaqCM)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Galmed Pharmaceuticals Ltd. is a biopharma company developing liver-disease therapies. It advances Aramchol, a first-in-class synthetic fatty acid–bile acid conjugate in Phase III for oral treatment of overweight or obese patients with prediabetes or type 2 diabetes who have nonalcoholic steatohepatitis (NASH). It also studies Aramchol in the ARRIVE Phase IIa trial for HIV-associated NASH with lipodystrophy. Other programs include Amilo-5MER, a five-amino-acid peptide, and MyBiotics in preclinical NASH and fibrosis. Galmed licenses Aramchol rights in Korea to Samil Pharma and collaborates with OnKai on an AI platform. Founded 2000, headquartered in Ramat Gan, Israel.

Company score

Sentiment: 0.19; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.10; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.16; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.06; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.12; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive